S. Whitebread

发表

Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets

Michael J. Keiser, B. Shoichet, J. Jenkins, 2012, Nature.

Mapping adverse drug reactions in chemical space.

M. Milik, A. Bender, J. Jenkins, 2009, Journal of medicinal chemistry.

Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure

A. Bender, J. Jenkins, J. Scheiber, 2007, ChemMedChem.

SPREAD—exploiting chemical features that cause differential activity behavior

Andreas Bender, Meir Glick, Ben Cornett, 2009 .

Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.

D. Bojanic, S. Whitebread, J. Hamon, 2005, Drug discovery today.

Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.

F. Lombardo, P. Atadja, S. Whitebread, 2011, Journal of medicinal chemistry.

Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data

A. Bender, J. Jenkins, E. Jacoby, 2007, ChemMedChem.

Reducing safety-related drug attrition: the use of in vitro pharmacological profiling

Gareth J Waldron, S. Whitebread, J. Hamon, 2012, Nature Reviews Drug Discovery.

In vitro safety pharmacology profiling: what else beyond hERG?

K. Azzaoui, S. Whitebread, J. Hamon, 2009, Future medicinal chemistry.

Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets

W. DuMouchel, B. Shoichet, Eugen Lounkine, 2017, eLife.

Matched molecular pair analysis: significance and the impact of experimental uncertainty.

Julian E. Fuchs, S. Whitebread, K. Liedl, 2014, Journal of medicinal chemistry.

The Importance of Reverse Translation for Preclinical Off-Target Mitigation: Quantification and Mitigation of Biases in the FDA Adverse Event Reporting System

B. Shoichet, Eugen Lounkine, S. Whitebread, 2017, bioRxiv.

The Powers and Perils of Post-Marketing Data Analysis: Quantification and Mitigation of Biases in the FDA Adverse Event Reporting System

B. Shoichet, Eugen Lounkine, S. Whitebread, 2016 .

Down regulation of the angiotensin II receptor subtype AT2 in human myometrium during pregnancy

S. Whitebread, K. Thomas, M. Kalenga, 1994, Regulatory Peptides.

Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1‐receptor subtype

S. Whitebread, P. Bühlmayer, M. Gasparo, 1993, British journal of pharmacology.

Pharmacological profile ofvalsartan: apotent, orally active, nonpeptide antagonist oftheangiotensin IIAT,-receptor subtype

S. Whitebread, L. Criscione, J. Wood, 1993 .

Should Cardiosafety be Ruled by hERG Inhibition? Early Testing Scenarios and Integrated Risk Assessment

S. Whitebread, W. Egan, Q. Lu, 2009 .

High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis

D. Bojanic, K. Azzaoui, S. Whitebread, 2006, Expert opinion on drug metabolism & toxicology.

Screening for Safety‐Relevant Off‐Target Activities

D. Mikhailov, K. Azzaoui, S. Whitebread, 2012 .

ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies.

Steven Whitebread, Yves P Auberson, Daniel Hoyer, 2007, Bioorganic & Medicinal Chemistry.

Secondary pharmacology: screening and interpretation of off-target activities - focus on translation.

S. Whitebread, L. Urban, B. Dumotier, 2016, Drug discovery today.

A receptor subtype involved in neuropeptide-Y-induced food intake

S. Whitebread, T. Branchek, D. Linemeyer, 1996, Nature.

Antialdosterones: incidence and prevention of sexual side effects.

J. Ménard, S. Whitebread, X. Jeunemaître, 1989, Journal of steroid biochemistry.

Valsartan: Preclinical and Clinical Profile of an Antihypertensive Angiotensin‐II Antagonist

W. A. Bradley, S. Whitebread, P. Bühlmayer, 1995 .

The activities of drug inactive ingredients on biological targets

Samuel T. Slocum, E. Berg, J. Irwin, 2020, Science.

Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes.

S. Whitebread, D. M. Melton, F. Spinale, 1997, Circulation.

Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro.

S. Whitebread, M. Biollaz, M. de Gasparo, 1987, The Journal of pharmacology and experimental therapeutics.

Inhibition of Food Intake by Neuropeptide Y Y5 Receptor Antisense Oligodeoxynucleotides

S. Whitebread, C. Gerald, L. Criscione, 1997, Diabetes.

Neuropeptide Y Y1 receptor antisense oligodeoxynucleotides enhance food intake in energy-deprived rats

S. Whitebread, A. Stricker-Krongrad, K. Hofbauer, 1998, Regulatory Peptides.

The pharmacology of neuropeptide Y (NPY) receptor-mediated feeding in rats characterizes better Y5 than Y1, but not Y2 or Y4 subtypes

S. Whitebread, L. Criscione, A. Stricker-Krongrad, 1998, Regulatory Peptides.

Translation of off-target effects: prediction of ADRs by integrated experimental and computational approach

J. Jenkins, Eugen Lounkine, S. Whitebread, 2014 .

Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.

S. Whitebread, D. M. Melton, F. Spinale, 1997, Circulation.

Experimental Studies AT 1 Angiotensin II Receptor Inhibition in Pacing- Induced Heart Failure: Effects on Left Ventricular Performance and Regional Blood Flow Patterns

S. Whitebread, F. Spinale, L. Hebbar, 1998 .

Preliminary biochemical characterization of two angiotensin II receptor subtypes.

S. Whitebread, M. de Gasparo, M. Gasparo, 1989, Biochemical and biophysical research communications.

Side Effects of Marketed Drugs: The Utility and Pitfalls of Pharmacovigilance

Eugen Lounkine, S. Whitebread, L. Urban, 2015 .

Cover Picture: Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off-Target Effects from Chemical Structure (ChemMedChem 6/2007)

A. Bender, J. Jenkins, J. Scheiber, 2007 .

Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen derivatives as neuropeptide Y Y5 receptor antagonists.

S. Whitebread, B. Nuesslein-Hildesheim, M. Gerspacher, 2004, Bioorganic & medicinal chemistry letters.

Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.

M. Lindvall, S. Whitebread, V. Sethuraman, 2018, Bioorganic & medicinal chemistry letters.

A peptide leptin antagonist reduces food intake in rodents

S. Whitebread, I. Leconte, M. Chiesi, 1999, International Journal of Obesity.

Left ventricular wall stress and sarcoplasmic reticulum Ca(2+)-ATPase gene expression in renal hypertensive rats: dose-dependent effects of ACE inhibition and AT1-receptor blockade.

S. Whitebread, H. Drexler, H. Baum, 1996, Cardiovascular research.

Angiotensin II AT2 receptors do not interact with guanine nucleotide binding proteins.

S. Whitebread, I. N. King, M. de Gasparo, 1991, European journal of pharmacology.

Breeding Butterflies and Moths - a Practical Handbook for British and European Species

S. Whitebread, A. Emmet, E. Friedrich, 1986 .

Radioiodinated CGP 42112A: a novel high affinity and highly selective ligand for the characterization of angiotensin AT2 receptors.

S. Whitebread, M. de Gasparo, B. Kamber, 1991, Biochemical and biophysical research communications.

Regulation of protease nexin-1 expression in cultured Schwann cells is mediated by angiotensin II receptors

S. Whitebread, D. Monard, M. de Gasparo, 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Angiotensin II receptor subtypes and cardiac function.

S. Whitebread, P. Erne, M. Brink, 1994, European heart journal.

Renal actions of the angiotensin AT2 receptor ligands CGP 42112 and PD 123319 after blockade of the renin-angiotensin system.

S. Whitebread, M. de Gasparo, F. Cumin, 1994, European journal of pharmacology.

Biochemical characterization of two angiotensin II receptor subtypes in the rat.

S. Whitebread, M. de Gasparo, H. Ramjoué, 1990, Journal of cardiovascular pharmacology.

Binding characteristics and vascular effects of various angiotensin II antagonists.

S. Whitebread, M. de Gasparo, P. Bühlmayer, 1990, Journal of cardiovascular pharmacology.

Renal actions of the selective angiotensin AT2 receptor ligands CGP 42112B and PD 123319 in the sodium-depleted rat.

S. Whitebread, M. de Gasparo, N. Levens, 1993, European journal of pharmacology.

2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists.

S. Whitebread, C. Leblanc, D. Budd, 2007, Bioorganic & medicinal chemistry letters.

Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives.

S. Whitebread, P. Furet, S. Stutz, 1991, Journal of medicinal chemistry.

Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series

Steven Whitebread, Marc de Gasparo, S. Whitebread, 1994 .

Binding of valsartan to mammalian angiotensin AT1 receptors

Steven Whitebread, Marc de Gasparo, S. Whitebread, 1995, Regulatory Peptides.

Translational Value of Preclinical Safety Assessment: System Organ Class (SOC) Representation of Off‐Targets

Eugen Lounkine, S. Whitebread, L. Urban, 2015 .

Predictive Toxicology: Latest Scientific Developments and Their Application in Safety Assessment

Dmitri Mikhailov, Steven Whitebread, Laszlo Urban, 2017 .

Steroidal, Aldosterone Antagonists: Increased selectivity of 9α,11-epoxy derivatives†‡§

S. Whitebread, H. Wehrli, M. Gasparo, 1997 .

Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor.

S. Whitebread, C. Gerald, L. Criscione, 1998, The Journal of clinical investigation.

The Angiotensin II AT2 Receptor Subtype

S. Whitebread, P. Furet, M. Gasparo, 1994 .

Leptin is a physiologically important regulator of food intake

S. Whitebread, H. Baum, M. Chiesi, 1997, International Journal of Obesity.

Potentiation of angiotensin II‐stimulated phosphoinositide hydrolysis, calcium mobilization and contraction of renal mesangial cells upon down‐regulation of protein kinase C

S. Whitebread, J. Pfeilschifter, J. Fandrey, 1990, FEBS letters.

Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis

Bin Chen, Andreas Bender, Meir Glick, 2009, J. Chem. Inf. Model..

Angiotensin II binding sites on micro-organisms contaminating cell cultures

S. Whitebread, J. Pfeilschifter, M. Gasparo, 1993, Regulatory Peptides.

Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.

S. Whitebread, I. Islam, J. Zhang, 2000, Bioorganic & medicinal chemistry letters.

AT1 angiotensin II receptor inhibition in pacing-induced heart failure: effects on left ventricular performance and regional blood flow patterns.

S. Whitebread, F. Spinale, M. de Gasparo, 1998, Journal of cardiac failure.

A screening pattern recognition method finds new and divergent targets for drugs and natural products.

Anne Mai Wassermann, Eugen Lounkine, Meir Glick, 2014, ACS chemical biology.

Targets Associated with Drug‐Related Suicidal Ideation and Behavior

S. Whitebread, J. Hamon, L. Urban, 2015 .

Localization of angiotensin II receptor subtypes in the rabbit heart.

S. Whitebread, M. Brink, G. Bullock, 1995, Journal of molecular and cellular cardiology.

[3H]AVP binding to rat renal tubular receptors during long-term treatment with an antagonist of arginine vasopressin

S. Whitebread, M. Gasparo, K. Hofbauer, 1988, Peptides.

Down-regulation of protein kinase C potentiates angiotensin II-stimulated polyphosphoinositide hydrolysis in vascular smooth-muscle cells.

S. Whitebread, J. Pfeilschifter, M. Ochsner, 1989, Biochemical Journal.

Ghrelin Acts on Leptin‐Responsive Neurones in the Rat Arcuate Nucleus

S. Whitebread, M. Traebert, E. Scharrer, 2002, Journal of neuroendocrinology.

The AT 2 Receptor: Historical Perspective

S. Whitebread, P. Furet, M. Gasparo, 2015 .

The AT2 Receptor

S. Whitebread, P. Furet, M. Gasparo, 2015 .

Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns.

S. Whitebread, F. Spinale, M. de Gasparo, 1998, Cardiovascular research.

Sarmesin is a partial agonst of angiotensin-II receptors in rabbit, but not in rat, aortic rings

S. Whitebread, M. Gasparo, L. Criscione, 1990 .

Effect of covalent dimer conjugates of angiotensin II on receptor affinity and activity in vitro.

S. Whitebread, M. de Gasparo, L. Criscione, 1991, Journal of Receptor Research.

In Vitro Safety Pharmacology Profiling: An Important Tool to Decrease Attrition

S. Whitebread, J. Hamon, 2009 .

Are the antibodies to a peptide complementary to angiotensin II useful to isolate the angiotensin II receptor?

S. Whitebread, M. Gasparo, K. Einsle, 1989, The Biochemical journal.

Secondary pharmacology: screening and interpretation of off-target activities - focus on translation.

S. Whitebread, L. Urban, B. Dumotier, 2016, Drug discovery today.